Gail Boudreaux

Gail Boudreaux, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Elevance Health, Inc. and Target Corp. Between 23 September 2021 and 17 July 2026, the trades on record add up to 21 filings.

In open-market terms, that means 3 purchases worth €1.5M on one side and 6 sales worth €15.6M on the other. Taken together, the sales exceed the purchases by €14.2M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 11 share grants. Since January 2026: 2 purchases and no sales on the market.

In size, the median ticket on the buying side is €575k. Clusters matter here: 2 out of 3 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

Most recently, on 17 July 2026, the filings show an open-market purchase worth €218k in Elevance Health, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.